Joseph Chiesa has more than 35 years of experience in the pharmaceutical industry working both for multinational pharmaceutical companies and CROs in the areas of medical affairs, medical research and marketing support. Joseph’s experience spans many therapeutic areas and geographical areas, gained whilst working as a regional medical manager, medical director and global therapeutic medical manager.
Throughout his career, he has supported the development of multiple client products in translation/early phases of development and provided leadership in protocol development, PK/PD, regulatory interactions and as Principal Investigator and medical monitor for phase I/II studies.
Joseph is best known for his leading role at the Covance Clinical Research Early Development Services, where he oversaw much of the pivotal work done on behalf of numerous clients, big and small for over a decade, predominantly as Principal Investigator in over 100 studies. This was during a period of immense change in both the regulatory rules governing First-in-Man studies, and in new approaches that allow much more information to be collected in early phases of drug development with combined protocols and biomarker development.
He has also held positions at Wellcome, Lepetit, ICI Pharmaceuticals, Servier, Zeneca, PharmOlam, Intercern, Chiltern, Kendle, Veeda and Covance.
Joseph graduated from the School of Medicine at the University of Buenos Aires in 1969, getting his Medical diploma in 1970 and his diploma of Clinical Pharmacologist in 1976. He received his Diploma of Specialist in Internal Medicine in 1981 and was granted the award of the best thesis from the Post Graduate School of the AMA for his thesis “Physiological and therapeutic roles of prostaglandins”.
He gained fellowship of the Faculty of Pharmaceutical Medicine (UK) in 1993. He is a former Fellow of the Institute of Clinical Research (UK), former Fellow of the Institute of Bio Medical Science (UK) and Chartered Scientist (UK). He was a Member of the Education Committee and Member of the Board of Examiners at the FPM and is at present a visiting professor at the University of Salvador (Argentina).
Managing Partner, Flic Gabbay said “Joseph will be an enormous asset to TranScrip, bringing both understanding of the challenges of early drug development as well as real practical insight into the challenge of working across strategic alliances. His depth of expertise in early drug development adds significantly to the wealth of experience already amassed in TranScrip and I personally am looking forward to his organisational support.”